Merck & Co., Inc.
Merck & Co., Inc. (MRK) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
mrk · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Merck & Co., Inc. (MRK) measures how much investors pay for each dollar of the company's trailing earnings. MRK's current PE ratio of 33.42x is calculated by dividing its stock price of $121.65 by its TTM earnings per share of $3.61. −80.2% discount vs 5Y avg 168.4x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 20 fiscal years · Front-end computedMinQ1 · 25%21.5x
MedianQ3 · 75%778.7x
Max
At 33.42x, MRK's current P/E is higher than in 75% of its annual fiscal year readings over the past 20 years — historically elevated.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - General · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Merck & Co., Inc.You MRK | $300.5B | 33.42x | +65.2% | $3.61 |
 Abbott Laboratories ABT | $157.7B | 33.55x | +65.9% | $3.73 |
 Amgen Inc. AMGN | $188.0B | 22.84x | +12.9% | $14.33 |
 AstraZeneca PLC AZN | $286.0B | 26.53x | +31.2% | $6.62 |
 Gilead Sciences, Inc. GILD | $161.1B | 17.94x | -11.3% | $6.84 |
 GSK plc GSK | $102.7B | 6.45x | -68.1% | $5.64 |
 Novo Nordisk A/S NVO | $185.9B | 14.05x | -30.5% | $23.03 |
Industry Average 6 peers with valid PE | — | 20.23x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 14.43x | $7.30 | -2.0% | |
2024-12-31 FY2024 | 14.72x | $6.76 | -98.1% | |
2023-12-31 FY2023 | 778.71x | $0.14 | +3924.6% | |
2022-12-31 FY2022 | 19.35x | $5.73 | +30.2% | |
2021-12-31 FY2021 | 14.86x | $5.16 | -46.8% | |
2020-12-31 FY2020 | 27.92x | $2.79 | +23.6% | |
2019-12-31 FY2019 | 22.60x | $3.84 | -25.6% | |
2018-12-31 FY2018 | 30.37x | $2.40 | -49.7% | |
2017-12-31 FY2017 | 60.43x | $0.89 | +53.5% | |
2016-12-31 FY2016 | 39.36x | $1.43 | +24.8% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Merck & Co., Inc. (MRK) measures how much investors pay for each dollar of the company's trailing earnings. MRK's current PE ratio of 33.42x is calculated by dividing its stock price of $121.65 by its TTM earnings per share of $3.61.
Frequently asked questions
MRK pe ratio · 6 questionsMRK's current PE ratio is 33.42x as of 2026-06-08, based on a stock price of $121.65 and TTM EPS of $3.61. Data sourced from Financial Modeling Prep via MRK's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Merck & Co., Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08